Pfizer vaccine may not be the best choice for frail people, but it's too early to make firm conclusions
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
WEDNESDAY, MAY 18, 2022
WEDNESDAY, MAY 18, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Pfizer vaccine may not be the best choice for frail people, but it's too early to make firm conclusions

World+Biz

Reuters
18 January, 2021, 06:20 pm
Last modified: 18 January, 2021, 06:22 pm

Related News

  • WHO advisory panel recommends extending use of Pfizer vaccine to 5-11 year olds
  • Pfizer set to oust AstraZeneca as top supplier of Covid-19 shots to poor nations
  • Study suggests Pfizer Covid-19 vaccine may only partially protect against Omicron
  • Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children
  • 7 lakh Chattogram people not vaccinated despite registration

Pfizer vaccine may not be the best choice for frail people, but it's too early to make firm conclusions

Norway has reported about 45,000 people around the country have been vaccinated against Covid-19 so far

Reuters
18 January, 2021, 06:20 pm
Last modified: 18 January, 2021, 06:22 pm
Pfizer's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration
Pfizer's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration

Reports of about 30 deaths among elderly nursing home residents who received the Pfizer vaccine have made international headlines.

With Australia's Therapeutic Goods Administration (TGA) expected to approve the vaccine imminently and the roll out set to begin next month, this development might seem like cause for concern around the safety of the vaccine.

But there are a few reasons it shouldn't be.

We haven't seen this issue reported in any other countries which are rolling out the Pfizer vaccine.

Norway has reported about 45,000 people around the country have been vaccinated against Covid-19 so far. Their vaccine program has mostly focused on residents in nursing homes.

In other countries, there may be more of a focus on frontline health-care workers in the first instance. So if there is any association between deaths in the elderly and this vaccine, it may not be apparent as yet.

It also depends on surveillance. Norway may have an especially rapid surveillance and reporting system in place, efficiently tracking everyone who has been vaccinated and quickly reporting any adverse outcomes.

We would expect surveillance reporting from other countries with an active vaccination program soon, increasing data critical to building a more accurate picture of vaccine safety across different populations.

Norway's reports will sensitise other countries to monitoring vaccine recipients closely, particularly those in nursing homes who are older and vulnerable. We may see further reports on this coming through in coming weeks from other countries.

But we also may not. We have limited information regarding these cases in Norway. The people reported to have died were elderly and very frail. Many had significant underlying health conditions common in the very old, and may have been nearing the end of their lives independent of the vaccine.

Though they are under investigation, it's important to note the deaths have not been linked conclusively to complications from the vaccine. Meanwhile, Australian experts have called for calm.

In the recent history of vaccines, we haven't seen any trends showing deaths in elderly people following vaccination. For example, there's no evidence the annual influenza vaccine has been associated with deaths in older people — or people of any age.

It's important to note though, that in making a comparison with the flu shot or another vaccine and the Pfizer vaccine for Covid-19, we're comparing apples and oranges.

The Pfizer vaccine is based on mRNA technology, which is completely new in a human vaccine. This technology introduces part of the genetic material of the SARS-CoV-2 virus in the form of messenger RNA (mRNA). This instructs your cells to make part of the virus which stimulates an immune response that inhibits infection and protects against disease.

All vaccines are designed to generate an immune response — albeit in different ways — to prepare our bodies to fight the virus if and when we encounter it.

Creating an immune response leads to inflammation in the body. Some people will experience no side effects from a vaccine, but the inflammation can manifest in different ways in different people and between different vaccines. This may mean a reaction at the site of the injection, or fatigue, or feeling unwell.

The deaths in Norway were reportedly associated with fever, nausea and diarrhoea, which, while at the severe end of the spectrum of vaccine side effects, would be tolerable for the vast majority of people.

How different people will respond to the mRNA is what we're starting to understand now. It's possible this vaccine will have more serious effects in older, vulnerable people where the initial inflammatory response could be overwhelming.

But it's still too early to draw any conclusions.

Vaccines need to generate an immune response in order to work, and side effects are a byproduct of our bodies mounting an immune response.

While the deaths are sad, they shouldn't be cause for alarm. This actually tells us the vaccine is stimulating an immune response. For most people that response will be entirely tolerable and lead to development of immune memory that protects you from severe Covid-19.

The big challenge for any vaccine is generating enough of an immune response so you're protected from the disease in question, but not too much that you experience serious adverse effects. Where this line in the sand exists will vary across different people, but the oldest and frailest vaccine recipients are likely to be most at risk of severe, potentially life-threatening reactions.

So for those who may be more susceptible, we may want to be a little more cautious. In approving the Pfizer vaccine, the TGA may consider advising against this particular vaccine for people who are very elderly and frail, particularly those who have other conditions and are potentially nearing the end of their lives.

Ideally, the vaccine should be considered on a case-by-case basis for this group, carefully weighing up the risks and benefits in each situation, based on the best available data.

Top News

Pfizer vaccine / Therapeutic Goods Administration

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Social safety budget to stay same despite inflation rise
    Social safety budget to stay same despite inflation rise
  • Graphics: TBS
    Facebook and Bangladeshi politicians: A new tide in mass political communication?
  • RMG makers worried over move on power tariff hike
    RMG makers worried over move on power tariff hike

MOST VIEWED

  • Mikhail Khodaryonok, a military analyst and retired colonel. Photo: Collected
    Ukraine will get worse for isolated Russia, analyst says on state TV
  • Service members of Ukrainian forces who have surrendered after weeks holed up at Azovstal steel works are seen inside a bus, which arrived under escort of the pro-Russian military at a detention facility in the course of Ukraine-Russia conflict in the settlement of Olenivka in the Donetsk Region, Ukraine May 17, 2022. REUTERS/Alexander Ermochenko
    Fears for Mariupol defenders after surrender to Russia
  • Smoke rises from the Duvha coal-based power station owned by state power utility Eskom, in Mpumalanga province, South Africa, 18 February, 2020. REUTERS/Mike Hutchings
    Pollution killing 9 million people a year, Africa hardest hit: Study
  • China's Vice Premier Liu He exits the office of the U.S. Trade Representative following a morning round of negotiations on the second day of last ditch trade talks in Washington, U.S., May 10, 2019. REUTERS/Leah Millis/Files
    China Vice Premier Liu soothes tech firms, supports overseas listings
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • A wounded service member of Ukrainian forces from the besieged Azovstal steel mill in Mariupol is transported on a stretcher out of a bus, which arrived under escort of the pro-Russian military in the course of Ukraine-Russia conflict in Novoazovsk, Ukraine May 16, 2022. REUTERS/Alexander Ermochenko
    Putin takes Mariupol, but wider Donbas victory slipping from reach

Related News

  • WHO advisory panel recommends extending use of Pfizer vaccine to 5-11 year olds
  • Pfizer set to oust AstraZeneca as top supplier of Covid-19 shots to poor nations
  • Study suggests Pfizer Covid-19 vaccine may only partially protect against Omicron
  • Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children
  • 7 lakh Chattogram people not vaccinated despite registration

Features

As the dynamics between global powers change, Bangladesh must be proactive to keep up its balancing act. Photo: Reuters

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

16m | Interviews
Graphics: TBS

Facebook and Bangladeshi politicians: A new tide in mass political communication?

1h | Panorama
Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

21h | Panorama
Illustration: TBS

How Putin revived Nato

23h | Panorama

More Videos from TBS

Paddle steamers in Bangladesh

Paddle steamers in Bangladesh

36m | Videos
Genome sequencing: best ways to diagnose pediatrics

Genome sequencing: best ways to diagnose pediatrics

1h | Videos
Reasons behind the sudden fall in stock market

Reasons behind the sudden fall in stock market

1h | Videos
The first mosque in India was built Prophet Mohammad time

The first mosque in India was built Prophet Mohammad time

14h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab